SEC Form 4 · accession 0001562180-18-004727
REGENXBIO Inc. · RGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Luke M Beshar
Director
Period of report
Nov 26, 2018
Accepted (ET)
Nov 28, 2018 · 4:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590877
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 26, 2018 | M | 1,721 | $49.45 | A | 1,721 | D | |
| Common Stock | Nov 26, 2018 | S | 1,721 | $65.00 | D | 0 | D | |
| Common Stock | Nov 27, 2018 | M | 883 | $49.45 | A | 883 | D | |
| Common Stock | Nov 27, 2018 | M | 4,687 | $22.00 | A | 5,570 | D | |
| Common Stock | Nov 27, 2018 | M | 6,250 | $18.85 | A | 11,820 | D | |
| Common Stock | Nov 27, 2018 | M | 6,250 | $12.74 | A | 18,070 | D | |
| Common Stock | Nov 27, 2018 | M | 716 | $3.76 | A | 18,786 | D | |
| Common StockF2 | Nov 27, 2018 | S | 18,786 | $65.03 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $49.45 | Nov 26, 2018 | M | 1,721 | D | — | May 25, 2028 | Common Stock | 1,721 | 8,175 | D |
| Stock Option (Right to Buy)F3 | $49.45 | Nov 27, 2018 | M | 883 | D | — | May 25, 2028 | Common Stock | 883 | 7,292 | D |
| Stock Option (Right to Buy)F4 | $22.00 | Nov 27, 2018 | M | 4,687 | D | — | Sep 16, 2025 | Common Stock | 4,687 | 0 | D |
| Stock Option (Right to Buy)F5 | $18.85 | Nov 27, 2018 | M | 6,250 | D | — | May 24, 2027 | Common Stock | 6,250 | 0 | D |
| Stock Option (Right to Buy)F6 | $12.74 | Nov 27, 2018 | M | 6,250 | D | — | Jun 1, 2026 | Common Stock | 6,250 | 0 | D |
| Stock Option (Right to Buy)F7 | $3.76 | Nov 27, 2018 | M | 716 | D | — | May 18, 2025 | Common Stock | 716 | 65,784 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- F2This transaction was executed in multiple trades at prices ranging from $65.00 to $65.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vests in 12 equal monthly installments following May 25, 2018.
- F4The previously granted option, representing a right to purchase a total of 9,375 shares, became exercisable as follows: the option vested in nine equal monthly installments following September 16, 2015.
- F5The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following May 24, 2017.
- F6The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following June 1, 2016.
- F7The previously granted option, representing a right to purchase a total of 80,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 24 months thereafter.